5th Annual Global Pharmacovigilance & Risk Management Summit

15th - 17th of June 2021

Klaudija Marijanović Barać

Sr Director, Global Patient Safety & PhV (TPC), Teva

“Additional risk minimisation measures implementation and
effectiveness evaluation “


Prior to the 5th Annual Global Pharmacovigilance and Risk Management Summit, the Chairperson Mircea Ciuca from CSL Behring held an exclusive Interview with Klaudija Marijanovic Barac from Teva Pharmaceuticals.

Klaudija Marijanović Barać is a physician with more than 18 years of experience in different  aspects of pharmacovigilance and different therapeutic areas. She started working in pharmaceutical industry in 2002, being one of the founders of Pharmacovigilance  Department in PLIVA Croatia. 

Klaudija will be holding a Case Study on Day Two!

Additional risk minimisation measures implementation and
effectiveness evaluation

  • Risk minimisation measures implementation and tracking
  • Updates and removal of additional measures
  • GVP XVI requirements with case studies and examples
  • Inspections on additional measures implementation and effectiveness evaluation

Do you feel you will benefit?

For registration details and group discounts, please contact:
Adrian Best

About The Speaker

Klaudija Marijanović Barać is a physician with more than 18 years of experience in different aspects of pharmacovigilance and different therapeutic areas. She started working in pharmaceutical industry in 2002, being one of the founders of Pharmacovigilance Department in PLIVA Croatia. She was Lead Safety Physician in Barr Group and established  RMP Group in Teva in 2015. She also led development of additional risk minimization  implementation tracking tool in Teva. At present she is Senior Director within Teva Periodic  reports and risk management Centre (TPC). Her team is supporting marketing authorizations  in the EU and on the international markets for generics, innovative, biological and biosimilar products. 
Klaudija holds diploma in Pharmacology and Pharmaceutical Medicine. She speaks on international congresses and is co-chair of the Pharmacovigilance workstream within  Medicines for Europe


The views, information, or opinions expressed during this interview for the 5th Annual Global Pharmacovigilance & Risk Management Summit are solely those of the individuals involved and do not necessarily represent TEVA and its employees.